Although extended-spectrum-␤-lactamase (ESBL)-producing aeromonads have been increasingly reported in recent years, most of them were isolates from case reports or environmental isolates. To investigate the prevalence of ESBL producers among Aeromonas blood isolates and the genes encoding ESBLs, consecutive nonduplicate Aeromonas blood isolates collected at a medical center in southern Taiwan from March 2004 to December 2008 were studied. The ESBL phenotypes were examined by clavulanate combination disk test and the cefepime-clavulanate ESBL Etest. The presence of ESBL-encoding genes, including bla TEM , bla PER , bla CTX-M , and bla SHV genes, was evaluated by PCR and sequence analysis. The results showed that 4 (2.6%) of 156 Aeromonas blood isolates, 1 Aeromonas hydrophila isolate and 3 Aeromonas caviae isolates, expressed an ESBL-producing phenotype. The ESBL gene in two A. caviae isolates was bla PER-3 , which was located in both chromosomes and plasmids, as demonstrated by Southern hybridization. Of four patients with ESBL-producing Aeromonas bacteremia, two presented with catheter-related phlebitis and the other two with primary bacteremia. Three patients had been treated with initial noncarbapenem ␤-lactams for 5 to 10 days, and all survived. In conclusion, ESBL producers exist among Aeromonas blood isolates, and clinical suspicion of ESBL production should be raised in treating infections due to cefotaxime-resistant Aeromonas isolates.
study was to investigate the prevalence of ESBL producers among Aeromonas blood isolates, to investigate the genes encoding ESBLs, and to describe the clinical features of infected patients. A literature review in search of clinical cases was also conducted, with the hope of better understanding the current status of ESBLs among clinical Aeromonas isolates.
MATERIALS AND METHODS
Bacterial isolates. Aeromonas blood isolates identified in the clinical microbiology laboratory of National Cheng Kung University Hospital (NCKUH), a university-affiliated medical center in southern Taiwan, from March 2004 to December 2008 were collected and stored at Ϫ70°C until use. For each patient, if multiple isolates of the same species with identical antimicrobial susceptibility profiles were obtained, only the first was taken into account. The genus Aeromonas was identified by the positive oxidase test, fermentation of D-glucose, motility, the absence of growth in 6.5% sodium chloride, and resistance to the vibriostatic agent O/129 (150 g), and the identification was confirmed by the API 20E system (BioMérieux, Marcy-l'Etoile, France). Identification of Aeromonas species was based on the sequence analysis of the partial rpoB gene by PCR with the primers Pasrpob-L (5Ј-GCAGTGAAAGARTTCTTTGGTTC-3Ј) and Rpob-R (5Ј GTTGCATGTTNGNACCCAT 3Ј) under the conditions previously described (12) . The sequences of amplified DNA products were compared with reference sequences available at the GenBank database using a BLAST search (http://www.ncbi.nlm.nih.gov/BLAST/).
Antimicrobial susceptibility tests. The ESBL phenotype was examined by tests proposed for the detection of ESBLs in Enterobacteriaceae by the Clinical and Laboratory Standards Institute (CLSI) (3) . Aeromonas isolates that demonstrated a diameter of inhibition zone of ceftazidime (30 g) of Յ22 mm or of cefotaxime (30 g) of Յ27 mm by the disk diffusion method-i.e., reduced susceptibility to expanded-spectrum cephalosporins-were examined by a phenotypic confirmatory test, i.e. the ceftazidime-clavulanate and cefotaxime-clavulanate combination disk test (CDT), and the cefepime-clavulanate ESBL Etest (AB Biodisk, Solna, Sweden). The presence of ESBL was determined by a Ն5-mm increase in zone diameters for ceftazidime/clavulanate, cefotaxime/clavulanate, or cefepime/clavulanate compared with those for ceftazidime, cefotaxime, or cefepime alone by CDT. Either a cefepime MIC reduction by Ն3 2-fold dilutions with clavulanate or a rounded phantom inhibition zone below the cefepime gradients with no ellipse visible around the cefepime end was also indicative of the presence of ESBL activity (30) . The MICs of doxycycline, imipenem, ertapenem, piperacillin-tazobactam, cefotaxime, ceftazidime, and levofloxacin for ESBL-producing isolates were determined by Etest, and the results were interpreted following CLSI recommendations for A. hydrophila complex (4). Genetic relatedness of ESBL producers of the same species was examined by arbitrarily primed PCR with primers ERIC-1R (5Ј-ATGTAAGCT CCTGGGGATTCAC-3Ј) and ERIC-2R (5Ј-AGTAAGTGACTGGGGTGAGC G-3Ј) (25) .
Detection of ESBL genes by PCR. For all phenotypically confirmed ESBLproducing Aeromonas isolates, PCR amplification, cloning, and DNA sequence analyses were conducted to determine the ESBL genotypes, including bla TEM , bla PER , bla CTX-M , and bla SHV genes, as well as the presence of the MBL bla CphA gene and the AmpC ␤-lactamase bla MOX gene by using previously described PCR primers and conditions (5, 17-19, 28, 34) (Table 1 ). The sequences of amplified DNA products were compared with the GenBank database to identify the types of ␤-lactamase genes.
Localization of the bla PER-3 gene. The location of the bla PER-3 gene was analyzed by using the S1 nuclease technique as described previously (22) . Southern hybridization was performed with a digoxigenin (DIG)-labeled bla PER-3 gene specific probe, obtained by PCR amplification with the primers PER-A(F) and PER-R1 (5Ј-CTCGTCTCCCTGATACGCTTTC-3Ј) using a DIG system (DIG DNA labeling and detection kit; Roche Diagnostics, Germany) according to the manufacturer's instructions (29) .
Patients and literature review. Medical records of patients with ESBL-producing Aeromonas bacteremia were reviewed to collect the clinical data. The severity of acute illness at the onset of Aeromonas bacteremia was assessed within 1 day after admission by the Pittsburgh bacteremia score, a previously validated scoring system that was based on mental status, body temperature, blood pressure, requirement for mechanical ventilation, and recent cardiac arrest (2) . Critical illness was defined as a Pittsburgh bacteremia score of Ն4 points. An English-language literature review was also conducted to find clinical cases of patients with ESBL-producing Aeromonas infections by querying the PubMed database between April 1993 and April 2011 with the keywords "Aeromonas" and "extended-spectrum beta-lactamase".
RESULTS
Isolates with the ESBL phenotype. During the study period, 156 consecutive nonduplicate Aeromonas blood isolates were collected. Fifty-five (35%) Aeromonas blood isolates with reduced susceptibility to expanded-spectrum cephalosporins were examined for the ESBL phenotype by the CDT and ESBL Etest. By CDT with ceftazidime, cefotaxime, and cefepime with and without clavulanate, a Ն5-mm increase in zone diameter was demonstrated in isolates of A. hydrophila A2-970201 (from patient A), Aeromonas caviae A2-970915 (patient B), A. caviae A2-971106 (patient C), and A. caviae A2-960104 (patient D). By ESBL Etest, the same four isolates demonstrated a MIC reduction by Ն3 2-fold dilutions with clavulanate. Overall, four isolates (2.6%) of 156 blood isolates, one A. hydrophila isolate and three A. caviae isolates, expressed ESBL phenotypes. Arbitrarily primed PCR of three A. caviae isolates showed three distinct gel patterns, suggestive of genetically unrelated strains. By Etest, all four ESBL producers were susceptible to imipenem, ertapenem, and levofloxacin and resistant to cefotaxime and ceftazidime. Two isolates were susceptible to cefepime, and three were susceptible to piperacillin-tazobactam. A profile of the antimicrobial susceptibility of these isolates is shown in Table 2 .
Detection of ESBL genes. Two A. caviae isolates, A2-970915 and A2-971106, carried the bla PER gene, which was 100% (927/927 nucleotides) identical to the complete sequence of the A. caviae ESBL bla PER-3 gene (GenBank accession number ; GenBank accession no. GQ152601) in A. hydrophila A2-970201, A. caviae A2-971106, and A. caviae A2-960104, were found ( Table 2) .
Localization of the bla PER-3 gene. The result of Southern hybridization for determining the localization of bla PER-3 gene in two A. caviae isolates demonstrated that the bla PER-3 gene was localized on both chromosomes and plasmids of these two isolates (Fig. 1) .
Patients and literature review. Clinical details of four patients with ESBL-producing Aeromonas bacteremia are shown in Table 3 . They developed Aeromonas bacteremia at 5 to 19 days after admission, and three (patients B, C, and D) did not receive antibiotics in the preceding 1 month. Two patients presented with catheter-related phlebitis, and two patients with cancers of the digestive tract presented with primary bacteremia; the Pittsburgh bacteremia scores of all four patients were less than 4. Three patients (B, C, and D) had been empirically treated with penicillin derivatives or cephalosporin for 5 to 10 days, and all four survived for at least 2 weeks after the onset of bacteremia.
A literature review found four clinical cases, including a pediatric patient with A. hydrophila sepsis and pneumonia (26) , an aged patient with necrotizing fasciitis caused by an A. hydrophila isolate harboring bla TEM-24 (7) , an aged patient with intestinal ischemia with a fecal isolate of A. caviae harboring bla TEM-24 (16) , and an aged patient with pneumonia caused by an A. caviae isolate harboring bla CTX-M-3 (35) ( Table 3) . Among three published cases with known clinical courses, the clinical conditions of two patients with pneumonia and one patient with necrotizing fasciitis deteriorated with initial noncarbapenem antimicrobial therapy.
DISCUSSION
To date, though there is no standard method for detection of ESBLs among aeromonads, most studies have adopted clavulanate-based synergy tests (7, 26) , such as those recommended for phenotypic confirmation of ESBL-producing Enterobacteriaceae by CLSI (3). However, using expanded-spectrum cephalosporins as ESBL substrates, antagonism by clavulanate on ESBL may be masked by the coexistence of AmpC ␤-lactamases. Aeromonas hydrophila and A. caviae isolates have been reported to possess chromosomal AmpC ␤-lactamase genes (11), as noted in our three isolates. Therefore, the synergy test with cefepime, a novel cephalosporin not hydrolyzed by AmpC (14) , and therefore the bla TEM-116 gene is not thought to be associated with ESBL activity. The bla PER-3 gene was first identified in an A. caviae isolate in France and was found to be located within the class 1 integron In39 (31) . Its product is the ESBL PER-3, and it is considered to be responsible for the ESBL activity in two A. caviae isolates in the present study. We further demonstrated that the bla PER-3 gene was located in both chromosome and plasmids of the two isolates. So far, this is the second report of bla PER-3 ESBL among aeromonads in the literature. The original acquisition of the bla PER-3 gene in A. caviae is undefined, but the bla PER-3 gene is closely related to the bla-PER-1 gene, with 99% identity (9) . Although ESBLs of the PER type were not the most common ESBLs identified, the spread of Enterobacteriaceae carrying the PER-1 ESBL gene as a chromosomal insert has been recently reported in Europe (23) .
Emergence of bla PER-1 ESBLs was also noted among ESBLproducing Acinetobacter baumannii and Pseudomonas aeruginosa isolates in Europe and Asia (6, 32) . Further, the horizontal transfer of mobile genetic elements, such as plasmids and integrons, was found to be attributable to an increasing incidence of multidrug resistance among environmental Aeromonas isolates (10). Therefore, it is possible that the bla PER gene was horizontally transferred by mobile genetic elements between aeromonads and coexistent waterborne bacteria in aquatic environments or between coexistent flora or pathogens in human beings. As with Aeromonas infections described previously (11, 33) , the clinical spectrum of patients with ESBL-producing Aeromonas infections in the present study and the literature included primary bacteremia, catheter-related infections, necrotizing fasciitis, pneumonia, and gastroenteritis. These infections occurred in both community and nosocomial settings. It is generally believed that patients acquire aeromonads from oral consumption of or direct mucocutaneous contact with contaminated water or seafood (11) , whereas the risk factors associated with acquisition of ESBL-producing Aeromonas infections are not known due to their rarity. Prior administration of antibiotics is one of the well-known risk factors for infections caused by other ESBL-producing Enterobacteriaceae (20) . However, most of our patients did not receive prior antibiotics, which made the association of prior exposure of antibiotics with development of ESBL-producing Aeromonas infections not evident. Further clinical investigations involving more patients are warranted to identify the risk factors for ESBL-producing Aeromonas infections, as well as surveillance of water from both hospitals and communities and suspicious foods to explore the possible sources of infections.
Although clinical studies have shown that survival was better with carbapenem treatment than with a cephalosporin among patients with bacteremia caused by ESBL-producing K. pneumoniae or Enterobacter cloacae (13, 21) , the optimal antimicrobial therapy for ESBL-producing Aeromonas infections is not standardized. Among three published cases, the clinical conditions of two patients with pneumonia and one patient with necrotizing fasciitis deteriorated with initial noncarbapenem antimicrobial therapy (7, 26, 35) . In contrast, our three patients, not critically ill as defined by their Pittsburgh bacteremia scores, remained stable with empirical noncarbapenem ␤-lactam agents, and all survived. The causes contributing to the poor outcome of previously published cases were not known. The difference in severity of illness at the time of antibiotic initiation, carriage and expression of toxins of each disease-causing aeromonad, or bacterial loads in clinical diseases might be the possible reasons. Theoretically carbapenems, not hydrolyzed by ESBLs, would work better than penicillins or cephalosporins against ESBL producers. However, antibacterial activity of carbapenems may be hampered by the production of bla CphA MBLs in A. hydrophila, A. veronii, and A. jandaei isolates, which is not easily detected by in vitro susceptibility tests unless a large inoculum is used (27) . It is too early to conclude the appropriateness of antimicrobial therapy from the clinical experiences of limited cases. Perhaps to avoid the complexity of ␤-lactamase production in clinical Aeromonas isolates, a fluoroquinolone could be the reasonable choice for invasive Aeromonas infections.
In conclusion, of 156 Aeromonas blood isolates, 4 (2.6%) exhibited the ESBL phenotype, and two A. caviae isolates possessed the bla PER-3 genes, which were located in both chromosomes and plasmids. The complexity of ␤-lactamase production increases among clinical Aeromonas isolates, and clinical use of ␤-lactam agents for invasive Aeromonas infections should be undertaken with caution.
